Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > mdgl downgrade

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jul 08, 2022 11:47am

103 Views

Post# 34811089

RE:RE:RE:RE:mdgl downgrade

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

MDGL -7.28%Jul. 08, 2022 11:39 AM ET

B Riley Securities has downgraded the clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ:MDGL) to Neutral from Buy, questioning the potential of a late-stage study for the company’s NASH candidate resmetirom to generate positive results this year.
NASH, also known as nonalcoholic steatohepatitis, is a chronic disease characterized by excessive fat accumulation in the liver that can cause chronic inflammation, leading to fibrosis (scarring), and eventually cirrhosis, liver failure, cancer, and death.
Madrigal (MDGL) expects the topline data from its MAESTRO-NASH biopsy study for resmetirom in 4Q 2022, seeking to file for the FDA’s accelerated approval next year.
B Riley analyst points to the study’s dual primary endpoints: NASH resolution and fibrosis improvement. While the former could lead to a favorable outcome, the analyst is not so convinced about the likely effect size on fibrosis improvement.
The price target lowered to $75 from $131 shares stands ~52% below the current average price target for Madrigal (MDGL) on Wall Street.